Hemogenyx Pharmaceuticals annual current ratio
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Current Ratio Growth & History (HEMO)
Hemogenyx Pharmaceuticals's current ratio was 1.38 for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.38 | 0.66 | +91.17% |
| 2024 | 2024-12-31 | 0.72 | −2.20 | −75.25% |
| 2023 | 2023-12-31 | 2.93 | −0.54 | −15.61% |
| 2022 | 2022-12-31 | 3.47 | −16.77 | −82.86% |
| 2021 | 2021-12-31 | 20.23 | 19.16 | +1777.29% |
| 2020 | 2020-12-31 | 1.08 | — | — |
Hemogenyx Pharmaceuticals quarterly current ratio
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 1.38 | 0.66 | +91.17% |
| Q2 2025 | 2025-06-30 | 0.43 | — | — |
| Q4 2024 | 2024-12-31 | 0.72 | — | — |
Hemogenyx Pharmaceuticals current ratio trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's current ratio increased from 1.08 to 1.38, a change of 0.31. The latest reported quarter, Q4 2025, shows 1.38.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as reported current assets divided by reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
